N J Carr1. 1. Department of Pathology, Royal Hospital Haslar, Gosport, Hampshire, United Kingdom.
Abstract
CONTEXT: The monoclonal antibody M30 recognizes a neoepitope of cytokeratin 18 produced during apoptosis. It is reactive in formalin-fixed, paraffin-embedded tissue and has great potential in the study of apoptosis in clinical and experimental material. OBJECTIVES: To compare the results of M30 immunoexpression with a more established technique of demonstrating apoptosis in tissue sections, in situ end-labeling. A secondary objective was to compare the results with immunoexpression of the proliferation-associated antigen Ki-67. DESIGN: Retrospective analysis of adenomas and adenocarcinomas of the large intestine. INTERVENTIONS: Immunohistochemistry for M30 and Ki-67, and in situ end-labeling. Formalin-fixed, paraffin-embedded tissue was used. MAIN OUTCOME MEASURES: The number of cells positive for M30, Ki-67, and in situ end-labeling, expressed as a proportion of the total number of cells counted. RESULTS: A strong positive correlation was found between in situ end-labeling and expression of M30, although the counts were widely scattered around the regression line. Counts of Ki-67 were strongly correlated with both M30 expression and in situ end-labeling. Immunoexpression of M30 was generally easier to interpret than in situ end-labeling, and the procedures for M30 immunohistochemistry were technically less exacting. CONCLUSION: These findings support the application of M30 immunoreactivity in the study of apoptosis.
CONTEXT: The monoclonal antibody M30 recognizes a neoepitope of cytokeratin 18 produced during apoptosis. It is reactive in formalin-fixed, paraffin-embedded tissue and has great potential in the study of apoptosis in clinical and experimental material. OBJECTIVES: To compare the results of M30 immunoexpression with a more established technique of demonstrating apoptosis in tissue sections, in situ end-labeling. A secondary objective was to compare the results with immunoexpression of the proliferation-associated antigen Ki-67. DESIGN: Retrospective analysis of adenomas and adenocarcinomas of the large intestine. INTERVENTIONS: Immunohistochemistry for M30 and Ki-67, and in situ end-labeling. Formalin-fixed, paraffin-embedded tissue was used. MAIN OUTCOME MEASURES: The number of cells positive for M30, Ki-67, and in situ end-labeling, expressed as a proportion of the total number of cells counted. RESULTS: A strong positive correlation was found between in situ end-labeling and expression of M30, although the counts were widely scattered around the regression line. Counts of Ki-67 were strongly correlated with both M30 expression and in situ end-labeling. Immunoexpression of M30 was generally easier to interpret than in situ end-labeling, and the procedures for M30 immunohistochemistry were technically less exacting. CONCLUSION: These findings support the application of M30 immunoreactivity in the study of apoptosis.
Authors: N C T van Grieken; G A Meijer; A zur Hausen; S G M Meuwissen; J P A Baak; E J Kuipers Journal: J Clin Pathol Date: 2003-05 Impact factor: 3.411
Authors: Jeffrey B Smerage; G Thomas Budd; Gerald V Doyle; Marty Brown; Costanza Paoletti; Maria Muniz; M Craig Miller; Madeline I Repollet; David A Chianese; Mark C Connelly; Leon W W M Terstappen; Daniel F Hayes Journal: Mol Oncol Date: 2013-03-14 Impact factor: 6.603
Authors: J Cummings; M Ranson; E Lacasse; J R Ganganagari; M St-Jean; G Jayson; J Durkin; C Dive Journal: Br J Cancer Date: 2006-07-03 Impact factor: 7.640
Authors: Uğur Koca; Çimen Gülben Olguner; Bekir Uğur Ergür; Emel Altekin; Aydın Taşdöğen; Seden Duru; Pelin Girgin; Kerim Gündüz; Serap Cilaker Mıcılı; Seda Güzeldağ; Muhammed Akkuş Journal: ScientificWorldJournal Date: 2013-02-13
Authors: Julia Alcaide; Rafael Funez; Antonio Rueda; Elisabeth Perez-Ruiz; Teresa Pereda; Isabel Rodrigo; Rafael Coveñas; Miguel Muñoz; Maximino Redondo Journal: BMC Clin Pathol Date: 2013-10-10